Abstract 249P
Background
PAEP encodes for pregnancy-associated endometrial alpha-2 globulin; a glycoprotein with a wide spectrum of biological actions. One of which is related to immune system modulation. In this work, we evaluated the prognostic potential of PAEP in ccRCC and its impact on tumor immune microenvironment (TIME).
Methods
The ccRCC cohort of the cancer genome atlas program (TCGA) was accessed to obtain relevant clinicopathological parameters alongside PAEP mRNA expression data. Multivariate Cox logistic regression analysis was applied to evaluate the prognostic independency of PAEP expression in predicting the overall survival (OS). Gene set enrichment analysis (GSEA) algorithm was implemented to discern the molecular mechanisms affected by PAEP upregulation. TIME was assessed by predicting the immune suppressive cells infiltration and T-cell dysfunction using TIMER 2.0 and TIDE, respectively.
Results
The Kaplan-Meier estimate showed that high expression of PAEP is associated with shortened OS (HR: 2.511, 95% CI: 1.864-3.384, P < .0001). Multivariate Cox logistic regression analysis depicts PAEP expression as an independent prognostic variable (HR: 1.849, 95% CI: 1.304-2.621, P = .001). GSEA (H1: Hallmarks of cancer gene sets) identified the following pathways to be involved in the poor prognostic signature of PAEP: epithelial-mesenchymal transition, G2M checkpoint, E2F targets, IL6/JAK/STAT3 signaling, coagulation, complement, KRAS downregulation, and inflammatory response. TIME showed a significant infiltration of several immunosuppressive cellular elements including regulatory T cells (ρ = 0.256, P < .0001), cancer-associated fibroblasts (ρ = 0.194, P < .0001), and myeloid-derived suppressor cells (ρ = 0.194, P < .0001). PAEP was not associated with a significant T-cell dysfunction (continuous z score = −0.787, P = .431).
Conclusions
PAPE is being identified as potential prognostic biomarker in ccRCC that impact TIEM.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
321P - Epidemiology and survival analysis of epithelial ovarian cancer: Results from comprehensive care center in north India
Presenter: Amit Badola
Session: Poster Display
Resources:
Abstract
322P - Evaluation of chemotherapy response score as a prognostic factor in advanced epithelial ovarian cancer: A prospective single centre study
Presenter: Upasana Palo
Session: Poster Display
Resources:
Abstract
323P - Platelet-to-lymphocyte ratio, neutrophil-to-lymphocyte ratio, and lymphocyte-to-monocyte ratio as prognostic biomarkers in ovarian cancer among the Asian population: A meta-analysis
Presenter: Wikania Wira Wiguna I Gede
Session: Poster Display
Resources:
Abstract
324P - All-<italic>trans</italic> retinoic acid sensitizes ovarian cancer to niraparib by inhibiting ALDH1A1 activity
Presenter: Bingjie Mei
Session: Poster Display
Resources:
Abstract
325TiP - A phase III randomized controlled trial in primary stage three and four ovarian cancer after interval cytoreductive surgery (FOCUS/KOV-HIPEC-04)
Presenter: Myong Cheol Lim
Session: Poster Display
Resources:
Abstract
327TiP - A single arm phase II study of single agent pemetrexed in platinum resistant/refractory epithelial ovarian or primary peritoneal cancer
Presenter: Swasthik Parampalli
Session: Poster Display
Resources:
Abstract
337P - Demographic patterns and survival outcomes of patients with T and NK-cell lymphoma at the National Cancer Centre Singapore
Presenter: Mohamed Haniffa Bin Hasan Mohamed
Session: Poster Display
Resources:
Abstract
338P - Multicenter real-world study of advanced-stage non-nasal type NK/T cell lymphoma (NKTCL): Clinical features, treatment and prognosis
Presenter: Yuce Wei
Session: Poster Display
Resources:
Abstract
339P - A comparison of survival of patients with relapsed or refractory diffuse large B cell lymphoma undergoing allogeneic stem cell transplantation or receiving CAR-T therapy
Presenter: Kenta Hayashino
Session: Poster Display
Resources:
Abstract
340P - The role of CT scans and laboratory tests for surveillance in patients with diffuse large B cell lymphoma who achieved complete remission after first-line chemotherapy
Presenter: YU Yagi
Session: Poster Display
Resources:
Abstract